In Px Wire, our quarterly newsletter, we looked at the strengths and limitations of new PEPFAR targets, new UNAIDS targets, new guidelines on ART and PrEP from the WHO and new Sustainable Development Goals.
In this excerpt from our centerspread graphic, we take a closer look at VMMC.
In Px Wire, our quarterly newsletter, we looked at the strengths and limitations of new PEPFAR targets, new UNAIDS targets, new guidelines on ART and PrEP from the WHO and new Sustainable Development Goals.
In this excerpt from our centerspread graphic, we take a closer look at the DREAMS program.
In this issue of Px Wire, our quarterly newsletter, we decipher the strengths and limitations of the multiple recent developments impacting HIV prevention: new PEPFAR targets, new UNAIDS targets, new guidelines on ART and PrEP from the WHO and new Sustainable Development Goals. What does each development mean, and how do advocates tailor their advocacy accordingly?
In this issue of Px Wire, our centerspread graphic looks at the sum total of the new targets and guidelines and gives our “take” on whether the current context is on target.
Now in its third year, this annual report, a collaboration between AVAC and the International AIDS Society Towards a Cure Initiative, analyzes global investment in HIV cure research.
Global Health Technologies presents an infographic overview of the many steps it takes to bring a product to market.
Advocates and researchers discussed data presented at IAS 2015, its implications and what’s next on the road to Durban 2016!
The US Women and PrEP Working Group and partners had a first-hand look at PrEP and transgender women — through the eyes of women prescribing it, using it, choosing not to use it, advocates calling for more research on it and policy-makers charged with integrating it into the national HIV response.
You can click here to view the video.
Slides are also available here.
A variety of safe and effective female condoms currently exist. However, regulatory hurdles limit new products from entering consumer markets. With the pipeline of new receptive-partner initiated condoms growing, advocates must understand how regulatory issues determine product introduction and approval in their country.
Receptive partner-initiated condoms in development
Link between regulatory environment and female condom access
Current regulatory issues and obstacles
Unique advocacy opportunity to break barriers to existing female condoms and pave the way for emerging internal condoms
You can watch the webinar here.
On May 18, advocates around the world observed HIV Vaccine Awareness Day (HVAD)—an annual commemoration of the need for and commitment to the ongoing search for a vaccine. AVAC convened a webinar—Vaccines in Vivo: Advances in AIDS Vaccine Research—and updated a number of materials, including our “HVAD Toolkit” for those interested in easy-to-digest research updates. This year brought the launch of long-awaited initiation of clinical trials building on positive results from the RV144 “Thai” trial. This effort is led by the Pox-Protein Public-Private Partnership (P5), including the HIV Vaccine Trials Network, who joined the webinar to provide a status update of their current vaccine research and development program. We also featured Janssen, part of Johnson & Johnson, to provide an overview of the research program they are moving forward that focuses on a cross-clade vaccine product.